Cipla USA, Inc. recalls
12 recall notices naming Cipla USA, Inc. since January 2025, in United States. The most recent was published 14 Oct 2026.
12recalls on record
Latest recalls (12)
- FDACipla USA, Inc. recalls Fosfomycin Tromethamine Granules for Oral SolutionFDAFailed Impurities/Degradation Specifications
- FDACipla USA, Inc. recalls Cinacalcet Hydrochloride TabletsFDACGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).
- FDACipla USA, Inc. recalls Cinacalcet Hydrochloride TabletsFDACGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit
- FDACipla USA, Inc. recalls Lanreotide InjectionFDALack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.
- FDACipla USA, Inc. recalls Nilotinib CapsulesFDAFailed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual…
- FDACipla USA, Inc. recalls Diclofenac Sodium Topical GelFDAFailed PH Specifications
- FDACipla USA, Inc. recalls Lanreotide InjectionFDAPresence of Particulate Matter.
- FDACipla USA, Inc. recalls Lanthanum Carbonate chewable tabletsFDAFailed stability specifications: Out of specification for hardness test
- FDACipla USA, Inc. recalls Cinacalcet Hydrochloride TabletsFDACGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.
- FDACipla Limited recalls Phytonadione Injectable EmulsionFDAFailed Stability Specifications: Observed OOS results: eg results for colour index
- FDACipla USA, Inc. recalls Albuterol SulfateFDAFailed Stability Specifications: Out of specification results was observed in Induction Port during the analysis of Particle size distribution at…
- FDACipla USA, Inc. recalls Budesonide Inhalation SuspensionFDALack of Assurance of Sterility: A market complaint was received for leakage and empty ampoule.